Oncology

Your Article Summary

See Latest Articles

Concurrent validity of the PSYCH-6, a very short scale for detecting anxiety and depression, among oncology outpatients
Australian and New Zealand Journal of Psychiatry, 06/22/09

Clover K et al. - The PSYCH-6 scale of the SPHERE-12 at a cut-off point of 3 is an equivalent instrument to the HADS-T for detecting cases and excluding non-cases of anxiety and depression and is suitable for deployment in oncology populations.

• Cross-sectional survey of 340 oncology outpatients attending a regional hospital in Newcastle, Australia.
• The performance of the PSYCH-6 against the Hospital Anxiety and Depression Scale (HADS) was evaluated using correlation, Cohen's kappa, positive agreement and negative agreement.

• The PSYCH-6 subscale of the SPHERE-12, at a cut-off point of 3, had substantial agreement with the total score of the HADS (HADS-T; κ = 0.73, p < 0.001).
• Negative agreement (0.92) was marginally higher than positive agreement (0.80).

Today in Side Effects...keeping you current

Receive free subspecialty "5-minute updates" via email

Menopausal symptoms in women undergoing chemotherapy-induced and natural menopause: a prospective controlled study
Annals of Oncology, 10/16/09

Effect of topical morphine (mouthwash) on oral pain due to chemotherapy- and/or radiotherapy-induced mucositis: a randomized double-blinded study
Journal of Palliative Medicine, 10/16/09

Amifostine for salivary glands in high-dose radioactive iodine treated differentiated thyroid cancer
Cochrane Reviews, 10/09/09

See All of Side Effects